# Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-dk-28-116-multimodal-ai-to-accelerate-precision-medicine-for-type/  
Official notice: https://www.grants.gov/search-results-detail/363678

> National Institutes of Health plans to offer grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expects to make one award worth $5.0 million in total. It is a forecast: the notice is expected around December 1, 2026, with applications due around February 10, 2027.

| Field | Value |
|---|---|
| Opportunity number | RFA-DK-28-116 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | expected February 10, 2027 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 1 |
| Total funding | $5.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.847 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

## What the grant funds

Type 1 diabetes (T1D) is a complex disease involving interactions among many different cell types, tissues, organs and biological processes. Genetics, the environment, and lifestyle all play a role in disease development and progression. Over the past two decades, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has supported major T1D research consortia covering basic, translational, and clinical research. Each consortium has focused on different aspects of T1D, such as specific organs, stages of disease or clinical outcomes. Together, these consortia have collected large longitudinal and multimodal datasets using standardized protocols and coordinated studies. While individual consortia have improved our understanding of specific areas, combining their work offers a rare opportunity to see how different biological processes interact to drive T1D development and progression. This integrated view can answer fundamental questions about T1D biology that cannot be answered using individual datasets or studies alone. Recent advances in artificial intelligence (AI) now make it possible to integrate these complementary datasets and study T1D across various tissues, disease stages, and biological levels. Building on these resources, NIDDK will support a coordinated, milestone-driven research project to answer fundamental questions about T1D biology and accelerate the development of personalized medicine. The project will combine multimodal human pancreas and clinical datasets to better understand how biological processes interact as T1D develops and progresses. The research will generate new insights into T1D biology, help us understand the different forms and stages of T1D, identify biomarkers, and inform new approaches for disease prevention, intervention, and treatment. To support the research, the project will develop and test advanced multimodal AI models. It will also develop AI-enabled research workflows, new methods to integrate data, and privacy-preserving synthetic datasets.

## Questions people ask

### Who can apply for Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)?

National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)?

Expected deadline February 10, 2027. Confirm the date and time in the official notice on Grants.gov.

### How much funding is available?

About $5.0 million in total for one award.